Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.

Details

Language :

English

ISSN :

0732183X

Volume :

40

Issue :

34

Database :

Supplemental Index

Journal :

Journal of Clinical Oncology

Publication Type :

Academic Journal

Accession number :

160430937

Full Text :

https://doi.org/10.1200/JCO.22.01207